Key differences between MS and NMOSD: clinical, imaging, and CSF findings

A 28-year-old female presents with bilateral optic neuritis and transverse myelitis extending over 3 vertebral segments. MRI spine shows a long central cord lesion at C3-C6. Serum AQP4-IgG is positive. How does NMOSD differ from MS clinically, on MRI, and in CSF analysis? Does she need disease-modifying therapy, and which agents are now approved specifically for NMOSD (eculizumab, inebilizumab, satralizumab)?